Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Alto Neuroscience Inc (ANRO)

Alto Neuroscience Inc (ANRO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 456,049
  • Shares Outstanding, K 31,066
  • Annual Sales, $ 0 K
  • Annual Income, $ -61,430 K
  • EBIT $ -66 M
  • EBITDA $ -66 M
  • 60-Month Beta 2.95
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.47

Options Overview Details

View History
  • Implied Volatility 275.05% (+58.87%)
  • Historical Volatility 114.38%
  • IV Percentile 66%
  • IV Rank 28.76%
  • IV High 756.33% on 05/16/25
  • IV Low 80.79% on 03/27/25
  • Expected Move (DTE 6) 3.10 (20.51%)
  • Put/Call Vol Ratio 0.50
  • Today's Volume 6
  • Volume Avg (30-Day) 301
  • Put/Call OI Ratio 0.15
  • Today's Open Interest 6,105
  • Open Int (30-Day) 5,718
  • Expected Range 12.03 to 18.23

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.56
  • Number of Estimates 5
  • High Estimate -0.47
  • Low Estimate -0.67
  • Prior Year -0.56
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.80 +40.09%
on 11/14/25
16.49 -8.25%
on 11/20/25
+0.93 (+6.55%)
since 11/12/25
3-Month
3.59 +321.45%
on 09/19/25
16.49 -8.25%
on 11/20/25
+11.24 (+288.95%)
since 09/12/25
52-Week
1.60 +845.63%
on 04/04/25
16.49 -8.25%
on 11/20/25
+11.30 (+295.04%)
since 12/12/24

Most Recent Stories

More News
Alto Neuroscience Reports Third Quarter 2025 Financial Results and Recent Business Highlights

– Successful outcome from FDA meeting on ALTO-207 in treatment-resistant depression; on track to initiate Phase 2b trial in the first half of 2026 and Phase 3 trial by early 2027 – ...

ANRO : 15.13 (+3.07%)
Alto Neuroscience to Participate in Upcoming Investor Conferences

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that...

ANRO : 15.13 (+3.07%)
Alto Neuroscience Announces $50 Million Private Placement Financing

– Financing led by Perceptive Advisors with participation from new and existing biotech focused investors – – Alto expects to use the proceeds of this financing...

ANRO : 15.13 (+3.07%)
Alto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting

– Successful outcome from recent FDA meeting guides Alto’s plan to accelerate development of ALTO-207, with capital from a $50 million private placement financing expected to enable the company to...

ANRO : 15.13 (+3.07%)
Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia

– ALTO-101, a novel PDE4 inhibitor, has demonstrated pro-cognitive effects in healthy volunteers – – Designation highlights the significant unmet need for new treatments...

ANRO : 15.13 (+3.07%)
Alto Neuroscience, Inc. Class Action Notice: ANRO Investors with Large Losses Should Contact Robbins LLP for Information About Leading the Securities Lawsuit

SAN DIEGO , Sept. 19, 2025 /PRNewswire/ -- Robbins LLP  reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired (a) Alto Neuroscience,...

ANRO : 15.13 (+3.07%)
Shareholders that lost money on Alto Neuroscience, Inc.(ANRO) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

NEW YORK , Sept. 19, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Alto Neuroscience, Inc. ("Alto Neuroscience, Inc." or the "Company") (NYSE: ANRO) of a class action...

ANRO : 15.13 (+3.07%)
Faruqi & Faruqi Reminds Alto Neuroscience Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 19, 2025 - ANRO

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Alto To Contact Him Directly To Discuss...

ANRO : 15.13 (+3.07%)
Investors in Alto Neuroscience, Inc. (ANRO): Protect Your Rights - Contact Levi & Korsinsky Before September 19, 2025

New York, New York--(Newsfile Corp. - September 18, 2025) - If you suffered a loss on your Alto Neuroscience, Inc. (NYSE: ANRO) investment and want to learn about a potential recovery under the federal...

ANRO : 15.13 (+3.07%)
Pomerantz Law Firm Announces the Filing of a Class Action Against Alto Neuroscience, Inc. and Certain Officers - ANRO

NEW YORK , Sept. 18, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Alto Neuroscience, Inc. ("Alto" or the "Company") (NYSE: ANRO) and...

ANRO : 15.13 (+3.07%)

Business Summary

Alto Neuroscience Inc. is a clinical-stage biopharmaceutical company. Its clinical-stage pipeline includes novel drug candidates in depression, PTSD, schizophrenia and other mental health conditions. Alto Neuroscience Inc. is based in LOS ALTOS, Calif.

See More

Key Turning Points

3rd Resistance Point 16.27
2nd Resistance Point 15.75
1st Resistance Point 15.44
Last Price 15.13
1st Support Level 14.61
2nd Support Level 14.09
3rd Support Level 13.78

See More

52-Week High 16.49
Last Price 15.13
Fibonacci 61.8% 10.80
Fibonacci 50% 9.05
Fibonacci 38.2% 7.29
52-Week Low 1.60

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar